User menu

Inhibitor development and mortality in non-severe hemophilia A

Bibliographic reference Eckhardt, C.L. ; Loomans, J.I. ; van Velzen, A.S. ; Peters, M. ; Mauser-Bunschoten, E.P. ; et. al. Inhibitor development and mortality in non-severe hemophilia A. In: Journal of Thrombosis and Haemostasis, Vol. 13, no. 7, p. 1217-1225 (2015)
Permanent URL
  1. Fijnvandraat K., Cnossen M. H., Leebeek F. W. G., Peters M., Diagnosis and management of haemophilia, 10.1136/bmj.e2707
  2. Franchini Massimo, Mannucci Pier Mannuccio, Hemophilia A in the third millennium, 10.1016/j.blre.2013.06.002
  3. Castaman, Haemophilia, 14, 15 (2008)
  4. Rodriguez-Merchan E. C., Rocino A., Literature review of surgery management in inhibitor patients, 10.1111/j.1365-2516.2004.00937.x
  5. Eckhardt C. L., van Velzen A. S., Peters M., Astermark J., Brons P. P., Castaman G., Cnossen M. H., Dors N., Escuriola-Ettingshausen C., Hamulyak K., Hart D. P., Hay C. R. M., Haya S., van Heerde W. L., Hermans C., Holmstrom M., Jimenez-Yuste V., Keenan R. D., Klamroth R., Laros-van Gorkom B. A. P., Leebeek F. W. G., Liesner R., Makipernaa A., Male C., Mauser-Bunschoten E., Mazzucconi M. G., McRae S., Meijer K., Mitchell M., Morfini M., Nijziel M., Oldenburg J., Peerlinck K., Petrini P., Platokouki H., Reitter-Pfoertner S. E., Santagostino E., Schinco P., Smiers F. J., Siegmund B., Tagliaferri A., Yee T. T., Kamphuisen P. W., van der Bom J. G., Fijnvandraat K., , Factor VIII gene (F8) mutation and risk of inhibitor development in nonsevere hemophilia A, 10.1182/blood-2013-02-483263
  6. FRANCHINI M., FAVALORO E. J., LIPPI G., Mild hemophilia A : Mild hemophilia A, 10.1111/j.1538-7836.2009.03717.x
  7. Hay, Thromb Haemost, 79, 762 (1998)
  8. PLUG I., VAN DER BOM J. G., PETERS M., MAUSER-BUNSCHOTEN E. P., DE GOEDE-BOLDER A., HEIJNEN L., SMIT C., WILLEMSE J., ROSENDAAL F. R., Mortality and causes of death in patients with hemophilia, 1992-2001: a prospective cohort study1, 10.1111/j.1538-7836.2006.01808.x
  9. Darby S. C., Kan S. W., Spooner R. J., Giangrande P. L. F., Hill F. G. H., Hay C. R. M., Lee C. A., Ludlam C. A., Williams M., , Mortality rates, life expectancy, and causes of death in people with hemophilia A or B in the United Kingdom who were not infected with HIV, 10.1182/blood-2006-10-050435
  10. Tagliaferri, Haemophilia, 16, 437 (2010)
  11. ECKHARDT C.L., MENKE L.A., VAN OMMEN C.H., VAN DER LEE J.H., GESKUS R.B., KAMPHUISEN P.W., PETERS M., FIJNVANDRAAT K., Intensive peri-operative use of factor VIII and the Arg593→Cys mutation are risk factors for inhibitor development in mild/moderate hemophilia A, 10.1111/j.1538-7836.2009.03357.x
  12. Darby S. C., Keeling D. M., Spooner R. J. D., Wan Kan S., Giangrande P. L. F., Collins P. W., Hill F. G. H., Hay C. R. M., , The incidence of factor VIII and factor IX inhibitors in the hemophilia population of the UK and their effect on subsequent mortality, 1977-99 : Inhibitors and mortality in hemophilia, 10.1046/j.1538-7836.2004.00710.x
  13. Rasi V., Ikkala E., Haemophiliacs with factor VIII inhibitors in Finland: prevalence, incidence and outcome, 10.1111/j.1365-2141.1990.tb06370.x
  14. Plug I., Thirty years of hemophilia treatment in the Netherlands, 1972-2001, 10.1182/blood-2004-05-2008
  15. Kasper, Thromb Diath Haemorrh, 34, 612 (1975)
  16. Verbruggen, Thromb Haemost, 73, 247 (1995)
  17. World Health Organization International Statistical Classification of Diseases and Related Health Problems 10th Revision
  18. VAN DER BOM J. G., TER AVEST P., VAN DEN BERG H. M., PSATY B. M., WEISS N. S., Assessment of incidence of inhibitors in patients with haemophilia, 10.1111/j.1365-2516.2009.02002.x
  19. Ahmad OB Boschi-Pinto C Lopez AD Murray CJL Lozano R Inoue M Age standardization of rates: a new who standard 2001
  20. Dean AG Sullivan KM Soe MM OpenEpi: Open Source Epidemiologic Statistics for Public Health
  21. Rothman, Epidemiologic Analysis with a Programmable Calculator: NIH publication, no. 79-1649 (1979)
  22. Franchini Massimo, Mannucci Pier Mannuccio, Co-morbidities and quality of life in elderly persons with haemophilia, 10.1111/j.1365-2141.2009.08005.x
  23. MAUSER-BUNSCHOTEN E. P., FRANSEN VAN DE PUTTE D. E., SCHUTGENS R. E. G., Co-morbidity in the ageing haemophilia patient: the down side of increased life expectancy, 10.1111/j.1365-2516.2009.01987.x
  24. Wight J., Paisley S., The epidemiology of inhibitors in haemophilia A: a systematic review, 10.1046/j.1365-2516.2003.00780.x
  25. MAUSER-BUNSCHOTEN E. P., DEN UIJL I. E. M, SCHUTGENS R. E. G, ROOSENDAAL G., FISCHER K., Risk of inhibitor development in mild haemophilia A increases with age : INHIBITORS IN MILD HAEMOPHILIA A, 10.1111/j.1365-2516.2011.02629.x
  26. KEMPTON C. L., SOUCIE J. M., MILLER C. H., HOOPER C., ESCOBAR M. A., COHEN A. J., KEY N. S., THOMPSON A. R., ABSHIRE T. C., In non-severe hemophilia A the risk of inhibitor after intensive factor treatment is greater in older patients: a case-control study : Inhibitors in mild and moderate hemophilia A, 10.1111/j.1538-7836.2010.04013.x